These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38927053)

  • 1. Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions.
    Cordani M; Garufi A; Benedetti R; Tafani M; Aventaggiato M; D'Orazi G; Cirone M
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
    Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
    Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaperone-mediated autophagy degrades mutant p53.
    Vakifahmetoglu-Norberg H; Kim M; Xia HG; Iwanicki MP; Ofengeim D; Coloff JL; Pan L; Ince TA; Kroemer G; Brugge JS; Yuan J
    Genes Dev; 2013 Aug; 27(15):1718-30. PubMed ID: 23913924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A degradative detour for mutant TP53.
    Vakifahmetoglu-Norberg H; Yuan J
    Autophagy; 2013 Dec; 9(12):2158-60. PubMed ID: 24145670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
    Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
    Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
    Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
    Elife; 2015 Aug; 4():. PubMed ID: 26271008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
    Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
    J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of p53 stability as a therapeutic strategy for cancer.
    Xu Z; Wu W; Yan H; Hu Y; He Q; Luo P
    Biochem Pharmacol; 2021 Mar; 185():114407. PubMed ID: 33421376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
    Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plakoglobin restores tumor suppressor activity of p53
    Alaee M; Nool K; Pasdar M
    Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
    Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
    Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
    Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
    Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.